Physician profile
DO Kim
NPI 1346542263
$508.02
in general payments reported to CMS, 2019-2025
11 companies · $76.05 in 2025
The $76.05 reported for 2025 was less than what a typical Nuclear Medicine provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.93 · 2022: $236 · 2023: $95.71 · 2024: $83.48 · 2025: $76.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $255.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $129.03 | 2022 | |
| Edwards Lifesciences Corporation | $89.21 | 2024-2025 | Sapien 3 Ultra Resilia |
| Bayer Healthcare Pharmaceuticals INC. | $73.57 | 2022-2025 | |
| Boston Scientific Corporation | $57.59 | 2022-2023 | Emblem Mri S-Icd, Lux-Dx Insertable Cardiac Monitor |
| Abiomed | $34.90 | 2022-2023 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.44 | 2022 | |
| Glaxosmithkline, LLC. | $23.14 | 2025 | Shingrix, Arexvy |
| Irhythm Technologies, INC. | $19.45 | 2023 | Zio Xt Patch |
| Janssen Pharmaceuticals, INC | $19.05 | 2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $16.93 | 2019 | |
| Merck Sharp & Dohme LLC | $15.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw DO Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.